- Bristol-Myers Squibb (NYSE:BMY) and Janssen Biotech (JNJ) will collaborate in a Phase 2 clinical trial assessing the combination of BMY's Opdivo (nivolumab) and Janssen's immunotherapy JNJ-64041757 in patients with non-small cell lung cancer (NSCLC).
-
JNJ-64041757 is an antigen-presentation therapeutic based on Live Attenuated Double-Deleted Listeria monocytogenes bacteria strains engineered to induce an immune response against NSCLC tumors. It is currently in Phase 1 development for lung cancer.
-
Opdivo is indicated for the treatment of NSCLC with progression on or after platinum-based chemo.